Current filters:


37 to 46 of 96546 results

Horizon Pharma buys US rights to Nuvo’s Pennsaid for $45 million


Canadian specialty drugmaker Nuvo Research says it has completed the sale of its osteoarthritis pain…

Anti-Arthritics/RheumaticsHorizon PharmaLicensingMallinckrodtNuvo ResearchPennsaidPharmaceuticalUSA

Indian government takes action on country’s growing mental health problems


Stigma, ignorance and a severe lack of doctors in India have long marred mental health care projects…

Human InterestIndiaNeurologicalPharmaceutical

GSK Ebola vaccine “too late” for current Ebola outbreak; more on Ebola


UK pharma giant GlaxoSmithKline says any Ebola vaccine it produces will come too late for the current…

Anti-viralsAVI-6002GlaxoSmithKlinePharmaceuticalProductionResearchSarepta Therapeutics

Profectus BioSciences gets US government funding for Ebola vaccine development


Under a one-year contract with US biotech firm Profectus BioSciences, the US Department of Health and…

Anti-viralsBiotechnologyFinancialProfectus BioSciencesResearchUSA

Pharmacyclics’ Imbruvica gains EU approval for two blood cancers


US drugmaker Pharmacyclics has received marketing approval from the European Commission for Imbruvica…

EuropeImbruvicaJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulation

New WikiLeaks revelations on Trans-Pacific Trade Pact Text


Access to affordable cancer treatments in the USA and 11 other countries would be delayed for years if…

Asia-PacificPatents & Trade marksPharmaceuticalPoliticsUSA

Pharmacyclics and Roche research Imbruvica and Gazyva

Pharmacyclics and Roche research Imbruvica and Gazyva


USA-based biopharma company Pharmacyclics has entered into a master clinical drug supply agreement with…


Virax to acquire AKTivate and deep AKT inhibitor portfolio


Australian biotechnology company Virax Holdings will acquire US oncology company AKTivate Therapeutics…

AKTivate TherapeuticsBiotechnologyMergers & AcquisitionsOncologyPathway OncologyVirax Holdings

37 to 46 of 96546 results

Back to top